China Resources Double Crane Unit Gets NMPA Approval for DC7001A Capsule Trial
China Resources Double Crane announced that its wholly-owned subsidiary Beijing Shuanghe Runchuang Technology Co. , Ltd. has recently received a Drug Clinical Trial Approval Notice from the National Medical Products Administration for the DC7001A capsule. The capsule is intended for the treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE).
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 30/100 and 50% confidence over a medium term horizon.
Healthcare · 13.1
Pharmaceuticals
- Direction
- positive
- Intensity
- 30
- Confidence
- 50%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 30
- Confidence
- 50%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.